← NewAmsterdam Pharma Co N.V. (NAMSW) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
NewAmsterdam Pharma Co N.V. (NAMSW)
Pharmaceutical Preparations · market cap $1.4B
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
5
programs
Upcoming events
0
next 90d+
Dossier
Not yet
generate it
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Obicetrapib | Phase 3 | Dyslipidemias |
| Obicetrapib 10mg | Phase 2 | Antioxidant Absorption |
| Obicetrapib 10 mg | Phase 2 | Preclinical Alzheimer's Disease |
| Ezetimibe 10mg | Phase 2 | Dyslipidemias |
| obicetrapib 10 mg + ezetimibe 10 mg FDC daily | Phase 3 | Lipidemia |
Price & technical context
3-month
+83.8%
6-month
+147.3%
12-month
+232.0%
52-wk range
$6.00–$29.97
vs 50-day MA
-4.0%
vs 200-day MA
+70.4%
Realized vol
100.4%
Max drawdown
-59.6%
Daily closes through 2025-12-11. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for NAMSW (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.